Once-daily, steroid-free treatment for patients down to 2 years of age1
A woman and young boy laughing A woman and young boy laughing
Not actual patients/caregiver.

Strong enough for mom, safe enough for her son too

VTAMA cream may help your patients with atopic dermatitis achieve clearer skin—with statistically significant itch relief as early as Day 2 in the pivotal studies.2-4

Not actual patients/caregiver.

VTAMA cream is a once-daily, steroid-free treatment for atopic dermatitis in patients down to 2 years of age1,2

VTAMA cream demonstrated:

vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis. vIGA-AD is a trademark of Eli Lilly and Co.

*In ADORING 1 and ADORING 2, vIGA-AD success, defined as vIGA-AD=0 or 1 and ≥2-grade improvement from baseline at Week 8, was achieved by 45% and 46% of patients on VTAMA cream vs 14% (P<0.0001) and 18% (P<0.0001) of patients on vehicle, respectively.2

Including patients who entered with vIGA-AD=0 (n=58) and patients entering with vIGA-AD≥1 who achieved vIGA-AD=0 at least once during the open label, LTE (n=320).5

Visible results*

Primary Endpoint Success†7
Age: 3
Gender: Male
Fitzpatrick Skin Type: II
Patient: 1028-007
Baseline
Week 2
Week 4
Week 8
Physician
Rated
vIGA-AD=3
EASI=11.6
Patient/Caregiver Rated
POEM=17
PP-NRS=4
Physician
Rated
vIGA-AD=3
EASI=11.2
Patient/Caregiver Rated
POEM=3
PP-NRS=1.9
Physician
Rated
vIGA-AD=1
EASI=1.4
Patient/Caregiver Rated
POEM=1
PP-NRS=1.6
Physician
Rated
vIGA-AD=1
EASI=1.6
Patient/Caregiver Rated
POEM=1
PP-NRS=0.1

Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): measure of AD severity with scores ranging from 0 (clear) to 4 (severe). vIGA-AD is a trademark of Eli Lilly and Co.
Eczema Area and Severity Index (EASI): measure of disease severity that incorporates body surface and lesion intensity into a composite score from 0 to 72, with higher scores indicating more severe disease.
Patient Oriented Eczema Measure (POEM): 7-item questionnaire to measure eczema severity focusing on the disease as experienced by the patient. Scores range from 0 to 28, with higher scores indicating more severe disease.
Peak Pruritus-Numeric Rating Scale (PP-NRS): patients are asked to rate their worst itch in the past 24 hours on a scale of 0 (no itch) to 10 (worst itch imaginable).

*Please note that these photographs are representative of one target lesion on individual patients treated with VTAMA cream during the pivotal clinical studies.

Primary endpoint success defined as vIGA-AD score of 0 (clear) or 1 (almost clear) and ≥2-grade improvement from baseline at Week 8.2

Patients may pay as little as
$0
for VTAMA cream*

MyVTAMA™ Savings Card

Your commercially insured patients may save today with the MyVTAMA Savings Program.

Commercially insured patients may pay as little as $0 and no more than $35.*

*Eligibility required. This offer is invalid for patients whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program.

IMPORTANT SAFETY INFORMATION

Indications: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for:

Adverse Events: In plaque psoriasis, the most common adverse reactions (incidence ≥1%) were: red raised bumps around the hair pores (folliculitis), pain or swelling in the nose and throat (nasopharyngitis), skin rash or irritation, including itching and redness, peeling, burning, or stinging (contact dermatitis), headache, itching (pruritus), and flu (influenza).
Adverse Events: In atopic dermatitis, the most common adverse reactions (incidence ≥1%) were: upper respiratory tract infection, red raised bumps around the hair pores (folliculitis), lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and stomach-area (abdominal) pain.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Back to top